Inhibikase Therapeutics Announces Publication Highlighting Mechanism of Disease and the Potential of Oral c-Abl Kinase Inhibitor Therapy for the Treatment of Parkinson's Disease
Inhibikase Therapeutics, Inc. (IKT)
Company Research
Source: PR Newswire
Impact Snapshot
Event Time:
IKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IKT alerts
High impacting Inhibikase Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IKT
News
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs [Yahoo! Finance]Yahoo! Finance
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsGlobeNewswire
- Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension [Yahoo! Finance]Yahoo! Finance
- Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial HypertensionGlobeNewswire
- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
IKT
Earnings
- 11/14/23 - Beat
IKT
Analyst Actions
- 3/5/24 - HC Wainwright
IKT
Sec Filings
- 4/19/24 - Form S-1
- 4/19/24 - Form 8-K
- 4/15/24 - Form PRE
- IKT's page on the SEC website